With respect to the tumor heterogeneity, targeting the PD-1/PD-L1 pathway showed a similar trend: relapsed tumors that acquired larger number of mutations became more heterogeneous (case 2 and case 4), whereas the tumor with lower number of acquired mutations became more homogeneous (case 3) (Fig. 5b). Here, CD274 is linked to neoplasm.